EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Preterm-birth-prevention with Lactobacillus crispatus oral probiotics: Protocol for a double blinded randomised placebo-controlled trial (the PrePOP study)

Gillian A Corbett, Siobhan Corcoran, Conor Feehily, Benedetta Soldati, Anthony Rafferty, David A MacIntyre, Paul D Cotter, Fionnuala M McAuliffe

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2024.107776 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Gillian A Corbett und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCD Perinatal Research Centre, UCD School of Medicine, University College Dublin, National Maternity Hospital, Dublin 2, Ireland; National Maternity …. Hauptthemen laut MEDLINE: Lactobacillus crispatus, Premature Birth, Probiotics, Vagina. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science Foundation Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Effective spontaneous preterm birth (sPTB) prevention is an urgent unmet clinical need. Vaginal depletion of Lactobacillus crispatus is linked to sPTB. This trial will investigate impact of an oral Lactobacillus spp. probiotic product containing an L. crispatus strain with other Lactobacilli spp., on the maternal vaginal and gut microbiome in pregnancies high-risk for sPTB. METHODS: A double-blind, placebo-controlled, randomised trial will be performed at the National Maternity Hospital Dublin, Ireland. Inclusion criteria are women with history of sPTB or mid-trimester loss, cervical surgery (cone biopsy or two previous large-loop-excision-of-transformation-zone) or uterine anomaly. The intervention is oral supplementation for twelve weeks with probiotic or identical placebo. The probiotic will contains: ◦ 4 billion CFU Lactobacillus crispatus Lbv 88(2x109CFU/Capsule) ◦ 4 billion CFU Lactobacillus rhamnosus Lbv 96(2x109CFU/Capsule) ◦ 0.8 billion CFU Lactobacillus jensenii Lbv 116(0.4x109CFU/Capsule) ◦ 1.2 billion CFU Lactobacillus gasseri Lbv 150(0.6x109CFU/Capsule). Investigators and participants will be blinded to assignment. RESULTS: The primary outcome is detectable L. crispatus in the vaginal microbiome after twelve weeks of treatment, measured using high-throughput DNA sequencing. A total of 126 women are required to detect a 25 % increase in detectable L. crispatus. Secondary outcomes include impact of intervention on the gut microbiome and metabolome, rate of sPTB and mid-trimester loss, neonatal outcomes and maternal morbidity. CONCLUSIONS: This randomised trial will investigate ability of an oral probiotic containing L. crispatus to increase its abundance in the vaginal microbiome, both directly by horizontal transfer and indirectly via microbiome and metabolome of the gut.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lactobacillus crispatusPremature BirthProbioticsVaginaAdultFemaleHumansPregnancyAdministration, OralDouble-Blind MethodGastrointestinal MicrobiomeIrelandLacticaseibacillus rhamnosusRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Alpha diversityMetagenomic sequencingMicrobiotaPregnancyVaginabeta diversity

Autor:innen und Institutionen

  • UCD Perinatal Research Centre, UCD School of Medicine, University College Dublin, National Maternity Hospital, Dublin 2, Ireland; National Maternity Hospital, Dublin 2, Ireland.
  • School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, United Kingdom.
  • National Maternity Hospital, Dublin 2, Ireland.
  • UCD Perinatal Research Centre, UCD School of Medicine, University College Dublin, National Maternity Hospital, Dublin 2, Ireland; Intuitive Health, 6 Main Street, Raheny, Dublin D05 Y9T2, Ireland.
  • March of Dimes Prematurity Research Centre, Division of the Institute of Reproductive and Developmental Biology, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, United Kingdom; Ro…
  • Teagasc Food Research Centre, Moorepark, Fermoy, Co.Cork, Ireland; APC Microbiome, University College Cork, Ireland.

Förderung

  • Science Foundation Ireland

Zitieren

APA

Corbett, G. A., Corcoran, S., Feehily, C., Soldati, B., Rafferty, A., MacIntyre, D. A., Cotter, P. D., & McAuliffe, F. M. (2025). Preterm-birth-prevention with Lactobacillus crispatus oral probiotics: Protocol for a double blinded randomised placebo-controlled trial (the PrePOP study). Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107776

Vancouver

Corbett GA, Corcoran S, Feehily C, Soldati B, Rafferty A, MacIntyre DA, et al. Preterm-birth-prevention with Lactobacillus crispatus oral probiotics: Protocol for a double blinded randomised placebo-controlled trial (the PrePOP study). Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2024.107776

BibTeX
@article{Corbett2025,
  author = {Corbett, Gillian A and Corcoran, Siobhan and Feehily, Conor and Soldati, Benedetta and Rafferty, Anthony and MacIntyre, David A and Cotter, Paul D and McAuliffe, Fionnuala M},
  title = {Preterm-birth-prevention with Lactobacillus crispatus oral probiotics: Protocol for a double blinded randomised placebo-controlled trial (the PrePOP study)},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2024.107776}
}
Kostenlos starten →